<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860623</url>
  </required_header>
  <id_info>
    <org_study_id>A16042015</org_study_id>
    <nct_id>NCT03860623</nct_id>
  </id_info>
  <brief_title>Effect of Oral Feeding on Gastric Emptying, Gut Blood Flow, and Hormone Responses in Obese and Healthy Weight Subjects</brief_title>
  <official_title>The Effect of Oral Feeding on Gastric Emptying, Small Bowel Water Content, Superior Mesenteric Artery Blood Flow, Plasma Hormone Concentrations and Blood Volume in Obese and Healthy Weight Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a complicated condition that is poorly understood. The aim of this study is to
      increase our knowledge of how the condition may arise, and what makes obese people remain
      obese.

      We will be investigating 12 people who are overweight and comparing them to 12 people who are
      lean, to look at how quickly food empties out of the stomach (gastric emptying) and travels
      through the gut, what the blood flow to the gut is, and also to examine the hormones which
      are involved in determining how full people feel after eating. In order to do this, we will
      be using a magnetic resonance imaging (MRI) scanner, and performing blood tests.

      The rate of gastric emptying may have an impact on satiety (how full one feels) and has been
      implied in the development of obesity. This effect has been shown to impact on subsequent
      meal intake to a greater degree in overweight subjects, and may be due to a difference in
      gastric emptying of food in overweight individuals, or to hormones such as ghrelin,
      glucagon-like peptide 1, and Peptide YY.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The World Health Organisation (WHO) has deemed being overweight or obese as the fifth leading
      cause for global deaths, with more than 1.9 billion adults being defined as overweight, and
      600 million defined as being obese. Conditions associated with obesity, such as stroke, type
      2 diabetes, certain cancers, cardiovascular, fatty liver and airway disease can lead to
      premature death. Obesity results from an imbalance in energy intake versus expenditure, and
      fat mass accumulates. Studies have indicated that obese animals have a faster gastric
      emptying time, a weaker contraction of the duodenum, but a stronger contraction and
      relaxation of the ileum, with associated changes in gastrointestinal neurohormonal levels.
      The rate of gastric emptying may have an impact on feelings of satiety and has been implied
      in the pathogenesis of obesity. Moreover, mesenteric blood flow increases 3-fold following a
      meal and in a swine experimental model, a reduction in weight gain was seen when blood flow
      was intentionally limited to the gut using flow-restricting endovascular stenting. The
      authors concluded that this intervention may play a role in the treatment of obesity where
      other interventions have failed or are inappropriate; however the role of blood flow to the
      gut in obese individuals is important to elucidate. We hypothesize that nutrient absorption
      in obese and healthy weight individuals after a standardized meal is determined by
      differences in gastric emptying and mesenteric blood flow which give rise to different
      insulin, glucose and gut hormone responses. These may be contributory mechanisms to the
      evolution or maintenance of obesity.

      The aim of this study is to establish the effects of food ingestion on gastric emptying,
      gallbladder emptying, small bowel water content and splanchnic blood flow as measured by
      serial magnetic resonance imaging (MRI) in the context of changes in plasma gastrointestinal
      hormone secretion in human subjects who are obese or healthy weight. In addition, this pilot
      study will provide the data necessary to power a larger study investigating methods of
      dietary manipulation in the treatment of obesity.

      Method: In order to normalize the pre-study diet, volunteers will have consumed a standard
      diet for the 3 days immediately before the study visit, which will be based on foods in their
      normal diet and will be designed to meet their estimated energy requirements and provide 15%
      of total daily energy intake as protein, 35% as fat and 50% as carbohydrate. Participants
      will report at 0800 hours following a fast from midnight and after having abstained from
      alcohol, nicotine, and caffeine from 1800 hours the day before. On arrival, participants will
      be given a drink of water (200ml). A retrograde cannula will be inserted into a dorsal foot
      vein after prior intradermal infiltration of 1% lidocaine, with the foot placed in a magnetic
      resonance (MR) compatible warming box that we have developed, for arterialized-venous blood
      sampling. Prior to baseline blood sampling, participants will undergo a magnetic resonance
      imaging (MRI) scan to determine baseline values for superior mesenteric artery (SMA) blood
      flow, small bowel water content and gastric fluid and gas volumes. Liver fat, visceral fat
      and subcutaneous fat volumes will also be assessed at this time. Subsequently, a blood sample
      will be drawn for analysis of concentrations of hemoglobin, glucose, insulin, glucagon-like
      peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), ghrelin and peptide YY (PYY). Serum
      osmolality will also be measured and subjective appetite assessed using visual analogue
      scales. The participants will then be given the test meal (in an upright, seated position)
      and asked to consume it within 15 minutes. The test meal will be comprised of pasta, cheese
      and tomato sauce, and provides 13% of total energy (E) from protein, 39%E fat, and 48%E
      carbohydrate.

      Following the test meal (time = 0 minutes), subjective appetite will be measured as before,
      then participants will be scanned at 30 minute intervals for 4 hours to assess gastric
      emptying, gastric accommodation, gastric motility and small bowel water content, as well as
      SMA blood flow. Blood samples will be drawn at 15 minutes, then every half hour until 240
      minutes after the test meal, with a final blood sample taken at 300 minutes. Subjective
      appetite will be assessed every hour over the 300 minute study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying rate</measure>
    <time_frame>240 minutes after feeding</time_frame>
    <description>time taken for a standard meal to empty from the stomach, assessed by serial volume measurements of the stomach using magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stomach volume in the fasted state</measure>
    <time_frame>baseline</time_frame>
    <description>volume of the stomach measured by magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superior mesenteric artery (SMA) blood flow in the fasted state</measure>
    <time_frame>baseline</time_frame>
    <description>blood flow in the SMA assessed using magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>superior mesenteric artery (SMA) blood flow response to feeding</measure>
    <time_frame>240 minutes after feeding</time_frame>
    <description>blood flow response to feeding, determined in the SMA every half hour using magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose concentration</measure>
    <time_frame>before feeding</time_frame>
    <description>whole blood glucose concentration assessed using a Hemocue glucose analyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose response to feeding</measure>
    <time_frame>300 minutes after feeding</time_frame>
    <description>whole blood glucose concentration response to feeding, assessed by serial sampling using a Hemocue glucose analyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin concentration</measure>
    <time_frame>baseline</time_frame>
    <description>serum insulin concentration in the fasted state measured at a later date using a radio-immunoassay (RIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum insulin response to feeding</measure>
    <time_frame>300 minutes after feeding</time_frame>
    <description>serum insulin concentration response to feeding, assessed by serial sampling and measured at a later date using a RIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma GLP-1 concentration</measure>
    <time_frame>baseline</time_frame>
    <description>Plasma GLP-1 concentration in the fasted state, measured at a later date using an enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GLP-1 response to feeding</measure>
    <time_frame>300 minutes after feeding</time_frame>
    <description>Plasma GLP-1 concentration response to feeding, assessed by serial sampling and measured at a later date using an ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma GLP-2 concentration</measure>
    <time_frame>baseline</time_frame>
    <description>Plasma GLP-2 concentration in the fasted state, measured at a later date using an enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GLP-2 response to feeding</measure>
    <time_frame>300 minutes after feeding</time_frame>
    <description>Plasma GLP-2 concentration response to feeding, assessed by serial sampling and measured at a later date using an ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma Ghrelin</measure>
    <time_frame>baseline</time_frame>
    <description>Plasma Ghrelin concentration in the fasted state measured at a later date using a RIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ghrelin response to feeding</measure>
    <time_frame>300 minutes after feeding</time_frame>
    <description>Plasma Ghrelin concentration response to feeding assessed by serial sampling and measured at a later date using a RIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma peptide YY (PYY)</measure>
    <time_frame>baseline</time_frame>
    <description>Plasma PYY concentration in the fasted state measured at a later date using a RIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma peptide YY (PYY) response to feeding</measure>
    <time_frame>300 minutes after feeding</time_frame>
    <description>Plasma PYY concentration response to feeding assessed by serial sampling and measured at a later date using a RIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective satiety in the fasted state</measure>
    <time_frame>baseline</time_frame>
    <description>Satiety of individuals in the fasted state will be assessed using 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and how full do you feel')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective satiety after eating</measure>
    <time_frame>immediately after eating the standard meal</time_frame>
    <description>Satiety immediately after eating the standard meal will be assessed using 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and 'how full do you feel')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective satiety response to eating</measure>
    <time_frame>300 minutes after eating</time_frame>
    <description>The satiety response to the standard meal will be assessed over the 300 minute study period using hourly collection of 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and 'how full do you feel')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visceral adiposity</measure>
    <time_frame>baseline</time_frame>
    <description>amount of visceral fat present, determined by MRI of the torso</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subcutaneous adiposity</measure>
    <time_frame>before feeding</time_frame>
    <description>thickness of the subcutaneous fat layer on the torso, determined by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic lipid content</measure>
    <time_frame>baseline</time_frame>
    <description>liver triacylglyceride content will be estimated using proton magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attrition rate</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants completing the protocol as a proportion of those who were recruited to the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>1 year</time_frame>
    <description>number of people volunteering to take part in the study as a proportion of those expressing initial interest</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Overweight</arm_group_label>
    <description>Otherwise healthy overweight and obese men (BMI 30-40kg/m2) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Weight</arm_group_label>
    <description>Healthy normal weight men (BMI 18-25kg/m2, but including those with BMI up to 28kg/m2 if waist circumference &lt;96cm) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Recruitment will be from the male population residing within 20 miles of the research site.
        This will include those from Nottinghamshire, Leicestershire and Derbyshire, UK
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 30-40 kg/m2

          -  BMI 18-25 kg/m2; those with BMI up to 28kg/m2 will be included if waist circumference
             is &lt;96cm.

          -  Males

          -  Aged 18-60yrs

        Exclusion Criteria:

          -  Acute illness in the preceding 6 weeks

          -  Taking regular medication

          -  History of deep vein thrombosis or clotting disorders

          -  Hypertension

          -  Diabetes

          -  Any clinically significant findings at screening

          -  History of substance abuse

          -  Demonstrating factors precluding safe MRI

          -  History of gastrointestinal motility disorders (e.g. gastroesophageal reflux disease
             -irritable bowel syndrome, gastroparesis, sphincter of Oddi dysfunction, etc.)

          -  Previous thoracic or abdominal surgery.

          -  Those who report having â‰¤3 bowel movements/week or &gt;2/day.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dileep Lobo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Bush, RGN</last_name>
    <phone>+44(0)115 823 1141</phone>
    <email>debbie.bush@nottingham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liz J Simpson, PhD</last_name>
    <phone>+44 (0) 115 8230128</phone>
    <email>liz.simpson@nottingham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>Notts</state>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Bush, RGN</last_name>
      <phone>+44 (0)115 823 1141</phone>
      <email>debbie.bush@nottingham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Liz Simpson, PhD</last_name>
      <phone>+44 (0)115 8230128</phone>
      <email>liz.simpson@nottingham.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dileep Lobo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs311/en/.</url>
    <description>WHO estimation of Global Overweight and Obesity</description>
  </link>
  <reference>
    <citation>Fu XY, Li Z, Zhang N, Yu HT, Wang SR, Liu JR. Effects of gastrointestinal motility on obesity. Nutr Metab (Lond). 2014 Jan 7;11(1):3. doi: 10.1186/1743-7075-11-3.</citation>
    <PMID>24398016</PMID>
  </reference>
  <reference>
    <citation>Vatner SF, Franklin D, Van Citters RL. Mesenteric vasoactivity associated with eating and digestion in the conscious dog. Am J Physiol. 1970 Jul;219(1):170-4.</citation>
    <PMID>4393203</PMID>
  </reference>
  <reference>
    <citation>Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterol Motil. 2015 Dec;27(12):1687-92. doi: 10.1111/nmo.12726. Review.</citation>
    <PMID>26598049</PMID>
  </reference>
  <reference>
    <citation>Hoad CL, Parker H, Hudders N, Costigan C, Cox EF, Perkins AC, Blackshaw PE, Marciani L, Spiller RC, Fox MR, Gowland PA. Measurement of gastric meal and secretion volumes using magnetic resonance imaging. Phys Med Biol. 2015 Feb 7;60(3):1367-83. doi: 10.1088/0031-9155/60/3/1367. Epub 2015 Jan 16.</citation>
    <PMID>25592405</PMID>
  </reference>
  <reference>
    <citation>Totman JJ, Marciani L, Foley S, Campbell E, Hoad CL, Macdonald IA, Spiller RC, Gowland PA. Characterization of the time course of the superior mesenteric, abdominal aorta, internal carotid and vertebral arteries blood flow response to the oral glucose challenge test using magnetic resonance imaging. Physiol Meas. 2009 Oct;30(10):1117-36. doi: 10.1088/0967-3334/30/10/011. Epub 2009 Sep 16.</citation>
    <PMID>19759401</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nottingham</investigator_affiliation>
    <investigator_full_name>Elizabeth Simpson</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>satiety</keyword>
  <keyword>gut blood flow</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>obesity</keyword>
  <keyword>incretin hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

